File attachments:
AttachmentSize
Thaller, Oncolytic virotherapy.pdf430.78 KB
Language
English
0
No votes yet
GlioblastomaCancerBrain CancerIntegrative Cancer TherapyCase SeriesOncolytic Virus TherapyNewcastle Disease VirusFront Oncol
. 2020 May 14;10:702. doi: 10.3389/fonc.2020.00702. eCollection 2020.
Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series
Benjamin Gesundheit 1, Eliel Ben-David 2, Yehudit Posen 1, Ronald Ellis 1, Guido Wollmann 3 4, E Marion Schneider 5, Karl Aigner 6, Lars Brauns 7, Thomas Nesselhut 8, Ingrid Ackva 9, Christine Weisslein 9, Arno Thaller 9
Affiliations expand
PMID: 32477944 PMCID: PMC7241257 DOI: 10.3389/fonc.2020.00702
Free PMC article
Abstract
Glioblastoma multiforme (GBM) remains an incurable condition, associated with a median survival time of 15 months with best standard of care and 5-year survival rate of <10%. We report on four GBM patients on combination treatment regimens that included oncolytic virus (OV) immunotherapy, who achieved clinical and radiological responses with long-term survival, thus far, of up to 14 years, and good quality of life. We discuss the radiological findings that provide new insights into this treatment, the scientific rationale of this innovative and promising therapy, and considerations for future research.
Keywords: Newcastle disease virus (NDV); biological therapy; glioblastoma; immunotherapy; oncolytic virotherapy.
Copyright © 2020 Gesundheit, Ben-David, Posen, Ellis, Wollmann, Schneider, Aigner, Brauns, Nesselhut, Ackva, Weisslein and Thaller.https://pubmed.ncbi.nlm.nih.gov/32477944/Arno Thaller